HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Grove, R. B. Articles by Goodyear, M. Search for Related Content PubMed PubMed Citation Articles by Grove, R. B. Articles by Goodyear, M.

Clinical Evaluation of Radiolabeled Bleomycin (BLEO) for Tumor Detection

Washington Hospital Center and George Washington University Medical Center, Washington, D.C.

Correspondence: For reprints contact: Richard C. Reba, Dept. of Nuclear Medicine, Washington Hospital Center, 110 Irving St., N.W., Washington, D.C. 20010.

ABSTRACT

Bleomycin (BLEO), a chemotherapeutic agent known to concentrate actively in certain types of neoplastic tissue, has been labeled in an effort to obtain a radiopharmaceutical of greater specificity and diagnostic accuracy for tumor localization. Studies have been completed on 15 patients using ⁵⁷Co and 9 patients using ¹¹¹In-BLEO and have been compared in each patient with ⁶⁷Ga-citrate. Semiquantitative analysis of the clinical scans with respect to visualization of the neoplastic lesions show that the use of ⁵⁷Co-BLEO did result in slightly higher sensitivity in the detection of tumors.